Trial Profile
Efficacy of natalizumab in patients with relapsing-remitting multiple sclerosis: a retrospective study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 05 Jan 2016 New trial record
- 01 Dec 2015 Results published in the Neurology and Therapy